Reports Q4 revenue $185.2M, consensus $185M. The company said, “Total revenues for the full year 2025 were $634.2 million, reflecting strong operational growth measured at constant exchange rates of 17% and a currency tailwind of ~$14 million. Fourth quarter total revenues were $185.2 million up 24%, or 20% at CER.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FOLD:
- Amicus Therapeutics (FOLD) Q4 Earnings Cheat Sheet
- Amicus presents new long-term data for Galafold, Pombiliti+ Opfolda
- Amicus Therapeutics: Solid Fundamentals but Limited Upside Amid BioMarin Takeover, Justifying Hold Rating
- Madrigal, Clene, Cencora, Sequans, Amicus: Insider Moves Exposed
- Amicus downgraded to Hold from Buy at Jefferies